10x Genomics, Inc. Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victor

Betting big on the future is not easy. Investing guru Cathie Wood attempts to discern the big ideas that will shape tomorrow and acts on them by buying large tranches of stock for her Ark Invest famil

Review 10x Genomics' (TXG) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

PLEASANTON, Calif. , May 2, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in

PALO ALTO, Calif.--(BUSINESS WIRE)--Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a decision in a court case has been made. The Eur

10x Genomics, Inc. (NASDAQ:TXG ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Cassie Corneau - Director of Investor Relations & Strategic Finance Serge Saxonov - Chi

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti

PLEASANTON, Calif. , April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 3

Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.

10x Genomics (TXG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimat

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PLEASANTON, Calif. , April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first q

Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution  PLEASANTON, Calif. , March 26, 2024 /PRNewswire/ -- 10x Genom

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue